Trials / Not Yet Recruiting
Not Yet RecruitingNCT06770088
Vunakizumab in Adults with Spondyloarthritis
A Prospective, Single-arm, Multicenter Study to Explore the Efficacy and Safety of Vunakizumab in Adults with Active Spondyloarthritis
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 880 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective, single-arm, multicenter study is aimed to explore the efficacy and safety of Vunakizumab in adults with spondyloarthritis. The primary endpoint is the proportion of adults with spondyloarthritis achieving ankylosing spondylitis assessment score (ASAS) 40 at week 16 in the treatment of Vunakizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vnacicizumab | Vunakizumab 120 mg subcutaneous injection at baseline and week2, week4, then every other 4 weeks. |
Timeline
- Start date
- 2025-01-10
- Primary completion
- 2026-01-10
- Completion
- 2027-12-31
- First posted
- 2025-01-13
- Last updated
- 2025-01-13
Source: ClinicalTrials.gov record NCT06770088. Inclusion in this directory is not an endorsement.